No headlines found.
No press releases found.
No news found.
The fund seeks long-term growth of capital. Normally investing at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness.
Fidelity Disruptive Medicine ETF trades on the NASDAQ stock market under the symbol FMED.
As of April 21, 2026, FMED stock price declined to $25.91 with 3,712 million shares trading.
FMED has a market cap of $60.21 million. This is considered a Micro Cap stock.
FMED has underperformed the market in the last year with a price return of +15.5% while the SPY ETF gained +35.2%. FMED has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.0% and +4.6%, respectively, while the SPY returned +4.2% and +6.9%, respectively.
FMED support price is $25.76 and resistance is $26.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FMED shares will trade within this expected range on the day.
